Johnson & Johnson orthopedic implants are most often discussed through DePuy Synthes, the company’s orthopaedics business for hip, knee, shoulder, trauma, spine, sports medicine, and related surgical technologies. In 2026, the main issue is not one implant model. It is the combination of a broad implant portfolio, a planned corporate separation announced on October 14, 2025, and continued investment in robotics, navigation, and procedure-specific systems. For patients, surgeons, and healthcare observers, the practical point is that implant brand matters, but it cannot be evaluated on its own. The product family, indication, fixation method, surgeon experience, registry evidence, recall history, and patient anatomy all affect the discussion around Johnson & Johnson orthopedic implants.
What Johnson & Johnson orthopedic implants include
Johnson & Johnson’s orthopaedics portfolio is operated through DePuy Synthes, a long-established orthopedic device business. Public company materials describe DePuy Synthes as covering joint reconstruction, trauma, extremities, craniomaxillofacial surgery, spinal surgery, sports medicine, and the VELYS digital surgery portfolio. That scope is broader than the common patient search term “joint replacement implants.” It includes permanent implants, fixation devices, instruments, robotic and navigation tools, planning platforms, and procedure support technologies.
The product mix can be viewed in several practical categories:
| Area | Examples of portfolio focus | Why it matters |
|---|---|---|
| Hip reconstruction | Total hip systems, stems, cups, heads, liners, navigation support | Used for arthritis, trauma-related degeneration, and other hip conditions when replacement is clinically indicated. |
| Knee reconstruction | Primary knee systems, revision knees, cemented and cementless options, robotic-assisted workflows | Knee choice depends on anatomy, ligament status, bone quality, activity level, and surgeon preference. |
| Shoulder reconstruction | Anatomic and reverse shoulder replacement platforms, including newer tissue-sparing instrumentation | Shoulder replacement is growing, but implant selection depends heavily on rotator cuff status and bone anatomy. |
| Trauma and extremities | Plates, screws, nails, wrist, clavicle, ankle, and fracture fixation systems | These products support fracture repair and stabilization rather than elective joint replacement alone. |
| Spine and related specialties | Interbody systems, fixation systems, craniomaxillofacial products, sports medicine devices | These devices serve different clinical pathways and should not be assessed using hip or knee evidence alone. |
For more coverage of medical device categories and implant-related industry updates, see the Implants section.
Why 2025 and 2026 are important for DePuy Synthes
The context for Johnson & Johnson orthopedic implants changed materially in late 2025. On October 14, 2025, Johnson & Johnson announced its intent to separate its Orthopaedics business. The company said the business would be named DePuy Synthes and that it was exploring multiple paths for the separation, with a targeted completion window of 18 to 24 months after the announcement. As of public company filings through the second quarter of 2026, the separation was still described as planned rather than completed.
That timeline matters for hospitals, surgeons, sales teams, distributors, and investors watching for possible changes in operating focus, research priorities, product support, and commercial strategy. It does not mean existing implants automatically change, procedures stop, or previously implanted devices need to be replaced. The status of any implant depends on the specific device, regulatory position, hospital purchasing agreements, and surgeon use.
Several recent events help explain the direction of the business:
| Date | Event | Practical significance |
|---|---|---|
| June 14, 2012 | Johnson & Johnson completed the Synthes acquisition and integrated it with DePuy. | This created the DePuy Synthes structure that still defines the orthopedic portfolio. |
| October 13, 2025 | Johnson & Johnson MedTech announced the U.S. launch of INHANCE INTACT for total shoulder arthroplasty. | The shoulder category became a visible innovation area within joint reconstruction. |
| October 14, 2025 | Johnson & Johnson announced its intent to separate the Orthopaedics business. | The orthopaedics portfolio entered a transition period, with DePuy Synthes expected to become a more focused business. |
| April 29, 2026 | The FDA posted Class II recall entries for certain ATTUNE Revision Hinge Femoral components. | The event illustrates why product-level recall checks matter, even for major brands. |
| May 26, 2026 | DePuy Synthes announced an agreement to acquire selective rights to Gemtrack radiofrequency tracking technology for joints. | The announcement points toward future navigation and robotic applications, subject to development and regulatory steps. |
| June 9, 2026 | DePuy Synthes announced U.S. commercial availability of VELYS Hip Navigation with AI Assistance. | The hip portfolio increasingly includes digital decision-support and navigation tools alongside implants. |
How the implant portfolio is positioned commercially
Johnson & Johnson’s 2025 Annual Report reported Orthopaedics franchise sales of about $9.3 billion in 2025, a 1.1% increase from 2024. Within that total, reported 2025 sales included approximately $1.67 billion in hips, $1.59 billion in knees, and $3.15 billion in trauma. The same report said hip growth was primarily due to new product launches, knee growth was driven by the ATTUNE portfolio and pull-through related to VELYS robotic-assisted solutions, and trauma growth reflected recently launched products and commercial execution.
In the second quarter of 2026, Johnson & Johnson reported 4.2% operational sales growth for Orthopaedics compared with the prior-year quarter. The company attributed hip growth to new product launches, knee growth to the ATTUNE portfolio and VELYS robotic-assisted pull-through, and trauma growth to recently launched products. These figures do not prove that one implant system is clinically superior to another. They do show where the company says business momentum is coming from: new launches, enabling technology, trauma products, and established joint reconstruction platforms.
For industry readers, DePuy Synthes appears to be positioned as a scale orthopaedics company with mature implant lines and newer digital tools. For patients, the more relevant point is narrower: commercial performance is not a substitute for an individualized surgical discussion.
Robotics, navigation, and AI are becoming part of the implant conversation
Modern orthopedic implant competition is no longer only about metal, polyethylene, ceramics, screws, and instruments. It increasingly includes software, navigation, imaging, preoperative planning, intraoperative feedback, and robotic-assisted execution. DePuy Synthes has emphasized the VELYS platform as part of this shift.
For knees, VELYS Robotic-Assisted Solution is designed for use with the ATTUNE Total Knee System. It supports planning and controlled bone preparation in total knee arthroplasty. For hips, the 2026 announcement of VELYS Hip Navigation with AI Assistance described a system intended to automate image interpretation, identify landmarks, and provide real-time information on leg length, offset, and cup position during total hip arthroplasty. Johnson & Johnson also stated that the AI model uses a human-in-the-loop design, meaning the surgeon retains control over final anatomical landmark placement.
The key limitation is that navigation and robotics are not guarantees of outcome. They may support consistency, visualization, and workflow, but patient recovery still depends on diagnosis, surgical indication, implant selection, component positioning, soft-tissue balancing, infection prevention, rehabilitation, and the patient’s health profile. A digital workflow can help a surgical team execute a plan; it does not replace clinical judgment.
Safety, recalls, and post-market evidence require product-level review
Orthopedic implants are regulated medical devices, and every implant system has benefits and risks. The FDA’s patient information on hip implants notes that the same implant system may have different outcomes in different patients. Factors such as device design, surgeon experience, implantation technique, age, sex, weight, activity level, and overall health can influence outcome and longevity.
That is why a broad search for “Johnson & Johnson orthopedic implants” should lead to more specific questions. Which model? Which generation? Which bearing surface? Cemented or cementless? Primary or revision? Which lot or UDI? What is the surgeon’s experience with that system? What registry or published data are available?
Recall history also needs careful interpretation. A recall does not always mean that all devices in a product family are unsafe. It may involve only certain lots, packaging, instruments, labels, or components. In April 2026, the FDA posted Class II recall entries involving certain DePuy Synthes ATTUNE Revision Hinge Femoral components. The listed reason for the cited entry was that external sterile packaging was found adhered to internal sterile packaging, potentially compromising sterility. The entry identified specific part, lot, and distribution information. That is a product-level and lot-level issue, not a reason to generalize across every ATTUNE or DePuy Synthes knee product. See also: Fixation.
Historical context is also relevant. DePuy Orthopaedics issued a voluntary recall of ASR hip systems in August 2010, and FDA records classify the ASR acetabular cup recall as a Class II recall. The ASR episode remains a reminder that implant surveillance, national registry data, revision rates, and long-term follow-up are essential. It should not be used to assume that all current DePuy Synthes hip, knee, shoulder, or trauma products carry the same risk profile.
Patients with existing implants should not self-diagnose device failure based on brand history. They should contact their orthopedic surgeon if they develop new or worsening pain, swelling, limp, change in walking ability, or unusual joint noises after surgery, especially when symptoms persist or appear months after implantation.
What the planned separation could mean for the orthopedic market
The planned separation of DePuy Synthes could make orthopaedics more strategically distinct from Johnson & Johnson’s remaining MedTech and Innovative Medicine businesses. Johnson & Johnson has said the separation is intended to enhance focus. Its public filings also caution that there is no assurance about the ultimate timing, completion, structure, or expected benefits of the transaction.
From an industry perspective, three areas deserve attention through 2026 and 2027. First, product support continuity will matter for hospitals that rely on implant trays, instruments, sales support, and revision compatibility. Second, investment priorities may become clearer as DePuy Synthes balances mature joint reconstruction franchises with digital surgery, trauma, and shoulder growth. Third, procurement teams may compare the company’s standalone focus with competitors that also bundle implants with robotics, navigation, data tools, and service contracts.
For patients, the separation should not be the main factor in choosing an implant. The decision should remain centered on the surgeon’s recommendation, the clinical indication, the specific implant system, known risks, expected recovery, and alternatives such as continued nonoperative care when appropriate.
Questions to ask before focusing on brand name
Brand recognition can help patients start a conversation, but it should not end the conversation. The following questions are more useful than asking whether a brand is simply “good” or “bad.”
- What exact DePuy Synthes or Johnson & Johnson implant system would be used, and why is it suitable for my anatomy and diagnosis?
- Is the planned implant for primary replacement, revision surgery, fracture fixation, or another indication?
- Will the implant be cemented, cementless, press-fit, modular, constrained, or unconstrained?
- What materials and bearing surfaces are involved, and what risks are specific to those materials?
- How many procedures has the surgeon performed with this implant family and surgical approach?
- Are robotics, navigation, patient-specific planning, or AI-assisted tools part of the procedure?
- What complications are most relevant for my health profile, including infection, loosening, instability, wear, fracture, stiffness, or need for revision?
- How will implant information be documented after surgery, including model, lot, and UDI details?
- Has the specific device or lot been affected by any recall or field safety action?
- What symptoms after surgery should trigger urgent contact with the care team?
The best implant discussion is specific, documented, and tied to the patient’s goals. A highly experienced surgeon may choose a familiar system because the instrumentation, sizing, fixation philosophy, and revision options fit the case. Another surgeon may choose a different system for equally valid reasons. The goal is not to chase a brand name, but to understand the clinical rationale.
Frequently asked questions
Are Johnson & Johnson orthopedic implants the same as DePuy Synthes implants?
In most orthopedic contexts, yes. Johnson & Johnson’s orthopaedics business is DePuy Synthes, and the product portfolio includes joint reconstruction, trauma, spine, sports medicine, extremities, and enabling technologies. The exact implant still needs to be identified by product family, model, and lot information.
Is ATTUNE a Johnson & Johnson knee implant?
ATTUNE is a DePuy Synthes knee platform within Johnson & Johnson MedTech’s orthopaedics portfolio. It includes different configurations and related technologies, so patients should ask which ATTUNE variant is being considered and whether it is intended for primary or revision knee replacement.
Does VELYS robotic technology choose or place the implant automatically?
No. VELYS technologies are surgical support tools. Public company descriptions emphasize planning, navigation, robotic assistance, and intraoperative information, while the surgeon remains responsible for clinical judgment and final surgical decisions.
Should patients choose an implant mainly by brand?
No. Brand is only one factor. Patients should discuss the exact implant system, surgeon experience, surgical approach, materials, fixation, expected benefits, risks, recovery plan, and any recall or safety information specific to the device or lot.
Has the DePuy Synthes separation already happened?
As of public filings and company announcements available through the second quarter of 2026, Johnson & Johnson continued to describe the Orthopaedics separation as planned, with a targeted completion window of 18 to 24 months after the October 14, 2025 announcement. Readers should check future company filings for completion updates.